Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by Eoganachton Mar 17, 2020 1:15am

83 Views

Post# 30815734

RE:RE:RE:RE:RE:RE:RE:Trials

Hi Hempdoc - it was Merck not the FDA that miscategorized the Theralase pdt as systemic.

Hempdoc wrote:

Yajne wrote: Eogonaght, I kinda like that they've described the TLD-1433 as "systemic" which in my view might suggest it's "immuno" effects. not sure if that was their intent in using the word "systemic"

I don't think that was their intention. For NMIBC, TLD 1433 is certainly not a systemic therapy. Systemic therapies are given orally or intravenously (I.e. drugs delivered via the bloodstream that can affect cells "throughout" the body). However, TLD 1433 can certainly trigger a "systemic" immunological response.

The fact the FDA miscategorized our therapy indicates how little they know about our treatment..lol. I do like the fact that at least one patient had the know how to make the crossover to TLD 1433. Some patients were lost to follow-up & there's a chance more than one has crossed over (or will), especially considering the relatively high comparator trial failure rates.

The key for any trial's success is providing the patient with a "clear" trial description during the informed consent process. A clear understanding of the treatment protocol & its risks is a primary determinant of patient enrollment, outside of a doctor's referral. The fact we have already treated at least 10 patients, including a crossover patient, indicates to me we are clearly meeting our objectives thus far. Of course, what gives us the big advantage is the simplicity of our treatment. Due to our treatment's simplicity/safety, I believe the Covid 19 crisis could actually boost enrollment. Covid 19 will primarily impact nonessential services/treatment imo. Good luck...